Complement Protein Isoforms in CSF as Possible Biomarkers for Neurodegenerative Disease

It has been suggested that the activation of the complement system is involved in the pathogenesis of several neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS). Here, the CSF expression levels of complement proteins C3b, C4b, factor...

Full description

Saved in:
Bibliographic Details
Published inDisease markers Vol. 21; no. 2; pp. 93 - 101
Main Authors Finehout, Erin J., Franck, Zsofia, Lee, Kelvin H.
Format Journal Article
LanguageEnglish
Published United States IOS Press 01.01.2005
Subjects
Online AccessGet full text
ISSN0278-0240
1875-8630
DOI10.1155/2005/806573

Cover

Abstract It has been suggested that the activation of the complement system is involved in the pathogenesis of several neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS). Here, the CSF expression levels of complement proteins C3b, C4b, factor B, and factor H were compared between normal subjects and patients diagnosed with AD, PD, MS, and neurosyphilis. The CSF proteins were initially separated using two‐dimensional gel electrophoresis, which allowed the comparison of some of the individual complement isoforms. Patients with AD, PD, and MS all showed more than one complement isoform with a significant change ( p < 0.05) in CSF expression level compared to normal subjects. PD patients were found to have the greatest number of significantly changed isoforms, all showing a decreased expression level in PD CSF. The complement isoforms examined were able to distinguish between some, but not all, of the diseases studied. The data suggest that when investigating a protein as a possible biomarker, it may be useful to compare individual protein isoform expression levels in addition to the more commonly measured total protein expression level.
AbstractList It has been suggested that the activation of the complement system is involved in the pathogenesis of several neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), and multiple sclerosis (MS). Here, the CSF expression levels of complement proteins C3b, C4b, factor B, and factor H were compared between normal subjects and patients diagnosed with AD, PD, MS, and neurosyphilis. The CSF proteins were initially separated using two‐dimensional gel electrophoresis, which allowed the comparison of some of the individual complement isoforms. Patients with AD, PD, and MS all showed more than one complement isoform with a significant change ( p < 0.05) in CSF expression level compared to normal subjects. PD patients were found to have the greatest number of significantly changed isoforms, all showing a decreased expression level in PD CSF. The complement isoforms examined were able to distinguish between some, but not all, of the diseases studied. The data suggest that when investigating a protein as a possible biomarker, it may be useful to compare individual protein isoform expression levels in addition to the more commonly measured total protein expression level.
It has been suggested that the activation of the complement system is involved in the pathogenesis of several neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS). Here, the CSF expression levels of complement proteins C3b, C4b, factor B, and factor H were compared between normal subjects and patients diagnosed with AD, PD, MS, and neurosyphilis. The CSF proteins were initially separated using two-dimensional gel electrophoresis, which allowed the comparison of some of the individual complement isoforms. Patients with AD, PD, and MS all showed more than one complement isoform with a significant change (p < 0.05) in CSF expression level compared to normal subjects. PD patients were found to have the greatest number of significantly changed isoforms, all showing a decreased expression level in PD CSF. The complement isoforms examined were able to distinguish between some, but not all, of the diseases studied. The data suggest that when investigating a protein as a possible biomarker, it may be useful to compare individual protein isoform expression levels in addition to the more commonly measured total protein expression level.It has been suggested that the activation of the complement system is involved in the pathogenesis of several neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS). Here, the CSF expression levels of complement proteins C3b, C4b, factor B, and factor H were compared between normal subjects and patients diagnosed with AD, PD, MS, and neurosyphilis. The CSF proteins were initially separated using two-dimensional gel electrophoresis, which allowed the comparison of some of the individual complement isoforms. Patients with AD, PD, and MS all showed more than one complement isoform with a significant change (p < 0.05) in CSF expression level compared to normal subjects. PD patients were found to have the greatest number of significantly changed isoforms, all showing a decreased expression level in PD CSF. The complement isoforms examined were able to distinguish between some, but not all, of the diseases studied. The data suggest that when investigating a protein as a possible biomarker, it may be useful to compare individual protein isoform expression levels in addition to the more commonly measured total protein expression level.
It has been suggested that the activation of the complement system is involved in the pathogenesis of several neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS). Here, the CSF expression levels of complement proteins C3b, C4b, factor B, and factor H were compared between normal subjects and patients diagnosed with AD, PD, MS, and neurosyphilis. The CSF proteins were initially separated using two-dimensional gel electrophoresis, which allowed the comparison of some of the individual complement isoforms. Patients with AD, PD, and MS all showed more than one complement isoform with a significant change (p < 0.05) in CSF expression level compared to normal subjects. PD patients were found to have the greatest number of significantly changed isoforms, all showing a decreased expression level in PD CSF. The complement isoforms examined were able to distinguish between some, but not all, of the diseases studied. The data suggest that when investigating a protein as a possible biomarker, it may be useful to compare individual protein isoform expression levels in addition to the more commonly measured total protein expression level.
Author Finehout, Erin J.
Franck, Zsofia
Lee, Kelvin H.
AuthorAffiliation School of Chemical and Biomolecular Engineering Cornell University Ithaca NY 14853 USA
AuthorAffiliation_xml – name: School of Chemical and Biomolecular Engineering Cornell University Ithaca NY 14853 USA
Author_xml – sequence: 1
  givenname: Erin J.
  surname: Finehout
  fullname: Finehout, Erin J.
– sequence: 2
  givenname: Zsofia
  surname: Franck
  fullname: Franck, Zsofia
– sequence: 3
  givenname: Kelvin H.
  surname: Lee
  fullname: Lee, Kelvin H.
BackLink https://www.ncbi.nlm.nih.gov/pubmed/15920296$$D View this record in MEDLINE/PubMed
BookMark eNqFkc1P3DAQxS0EgmXbU--VT1yqwDi2E_uCRJdPCdGVoOrRcpIJdUnixc4i8d_j1VIoFRIn25qfn968t0s2Bz8gIV8Y7DMm5UEOIA8UFLLkG2TCVCkzVXDYJBPIS5VBLmCH7Mb4B4DlWuhtssOkziHXxYT8mvl-0WGPw0jnwY_oBnoRfetDH2m6z65PqY107mN0VYf0u_O9DXcYIk0MvcJl8A3e4oDBju4B6bGLaCN-Ilut7SJ-fj6n5Ofpyc3sPLv8cXYxO7rMasFgzKRouQAQZa2LSirFrVJaCAXpWWBlRVULWwK3orEVB14VeaOV1kpJ0bRa8Sk5XOsullWPTZ32CLYzi-CSzUfjrTNvJ4P7bW79g-FKMlA6Cew9CwR_v8Q4mt7FGrvODuiX0RSlKrnQ5Ycg01xwKSCBX_-19OLlb-gJ-LYG6pBiDdi-ImBWlZpVpWZdaaLZf3TtxpS1X-3junf_PAEMXKKQ
CitedBy_id crossref_primary_10_1586_epr_09_91
crossref_primary_10_1093_brain_awq085
crossref_primary_10_1002_jcb_23204
crossref_primary_10_1016_j_nbd_2010_04_020
crossref_primary_10_1016_j_jprot_2010_11_010
crossref_primary_10_1002_prca_200900065
crossref_primary_10_1186_s12974_021_02225_9
crossref_primary_10_3390_md20010018
crossref_primary_10_1179_1743132815Y_0000000075
crossref_primary_10_1007_s00702_012_0797_8
crossref_primary_10_1111_j_1471_4159_2009_06558_x
crossref_primary_10_1016_j_hoc_2015_06_006
crossref_primary_10_3389_fncel_2014_00380
crossref_primary_10_1111_j_1600_0404_2007_00985_x
crossref_primary_10_1093_brain_awl279
crossref_primary_10_1111_j_1365_2249_2008_03830_x
crossref_primary_10_1586_epr_10_75
crossref_primary_10_1007_s00702_008_0070_3
crossref_primary_10_1016_j_jprot_2010_01_004
crossref_primary_10_1016_j_euprot_2014_02_003
crossref_primary_10_1021_pr070220c
crossref_primary_10_1016_j_bbrc_2006_02_051
crossref_primary_10_1002_jcb_23113
crossref_primary_10_1016_j_imbio_2011_07_023
crossref_primary_10_1038_s41536_023_00311_5
crossref_primary_10_1586_14789450_3_1_45
crossref_primary_10_3389_fneur_2024_1360222
crossref_primary_10_3389_fgene_2022_892491
crossref_primary_10_1186_1750_1326_9_22
crossref_primary_10_1111_ner_13075
crossref_primary_10_1186_s13195_023_01377_5
crossref_primary_10_1371_journal_pone_0016032
crossref_primary_10_3233_JAD_231235
crossref_primary_10_1007_s00702_018_1857_5
crossref_primary_10_1186_alzrt266
crossref_primary_10_1016_j_jprot_2011_05_042
crossref_primary_10_1002_pmic_200600284
crossref_primary_10_1007_s00702_017_1792_x
crossref_primary_10_3389_fncel_2023_1094106
crossref_primary_10_3390_brainsci11111515
crossref_primary_10_1007_s12035_013_8519_2
crossref_primary_10_1016_j_ajpath_2011_01_006
crossref_primary_10_1186_s12903_023_03846_7
crossref_primary_10_1007_s11064_008_9588_x
crossref_primary_10_1586_14789450_5_1_1
crossref_primary_10_3389_fncel_2014_00369
crossref_primary_10_2139_ssrn_4118345
crossref_primary_10_3233_JAD_180833
crossref_primary_10_1002_pmic_201500167
crossref_primary_10_1007_s10571_019_00700_9
crossref_primary_10_1016_j_jprot_2013_01_025
crossref_primary_10_1016_j_nurx_2006_05_001
crossref_primary_10_3389_fimmu_2022_1055050
crossref_primary_10_1586_14789450_4_2_227
crossref_primary_10_12688_f1000research_6801_2
crossref_primary_10_1186_s13195_020_00628_z
crossref_primary_10_12688_f1000research_6801_1
crossref_primary_10_1042_CS20230513
crossref_primary_10_1002_elps_201300609
crossref_primary_10_1093_brain_awaa425
crossref_primary_10_3233_JAD_151075
crossref_primary_10_3892_ijmm_2013_1267
crossref_primary_10_1002_prca_200800251
crossref_primary_10_1016_j_parkreldis_2008_05_014
crossref_primary_10_1586_14737159_7_5_635
crossref_primary_10_1007_s40291_013_0069_9
ContentType Journal Article
Copyright Copyright © 2005 Hindawi Publishing Corporation. 2005
Copyright_xml – notice: Copyright © 2005 Hindawi Publishing Corporation. 2005
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7X8
5PM
DOI 10.1155/2005/806573
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Neurosciences Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList CrossRef

MEDLINE - Academic
MEDLINE
Neurosciences Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1875-8630
EndPage 101
ExternalDocumentID PMC3851089
15920296
10_1155_2005_806573
Genre Research Support, U.S. Gov't, Non-P.H.S
Research Support, U.S. Gov't, P.H.S
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIMH NIH HHS
  grantid: R01MH59926
GroupedDBID ---
.GJ
0R~
24P
29G
36B
4.4
53G
5GY
5RE
5VS
AAFNC
AAFWJ
AAJEY
AAYXX
ABJNI
ABUBZ
ACCMX
ACGFS
ACIWK
ACPQW
ACPRK
ADBBV
ADRAZ
ADZMO
AENEX
AFRAH
AFRHK
AGIAB
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CAG
CITATION
COF
DIK
DU5
EBS
EJD
EMB
F5P
H13
HYE
HZ~
IHR
IL9
INR
IOS
IPNFZ
KQ8
M48
MET
MIO
O9-
OK1
P2P
RIG
RNS
RPM
ZGI
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7TK
7X8
5PM
ID FETCH-LOGICAL-c410t-54f340047c96b5883a889448096b6eba4bc4a703a4dab303b62d98998854df983
IEDL.DBID M48
ISSN 0278-0240
IngestDate Thu Aug 21 18:01:51 EDT 2025
Fri Sep 05 04:15:02 EDT 2025
Thu Sep 04 20:08:43 EDT 2025
Mon Jul 21 05:59:23 EDT 2025
Tue Jul 01 04:22:06 EDT 2025
Thu Apr 24 22:55:08 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c410t-54f340047c96b5883a889448096b6eba4bc4a703a4dab303b62d98998854df983
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1155/2005/806573
PMID 15920296
PQID 19343540
PQPubID 23462
PageCount 9
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3851089
proquest_miscellaneous_67873497
proquest_miscellaneous_19343540
pubmed_primary_15920296
crossref_primary_10_1155_2005_806573
crossref_citationtrail_10_1155_2005_806573
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2005-01-00
2005-00-00
20050101
PublicationDateYYYYMMDD 2005-01-01
PublicationDate_xml – month: 01
  year: 2005
  text: 2005-01-00
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Disease markers
PublicationTitleAlternate Dis Markers
PublicationYear 2005
Publisher IOS Press
Publisher_xml – name: IOS Press
SSID ssj0012949
Score 1.9870707
Snippet It has been suggested that the activation of the complement system is involved in the pathogenesis of several neurodegenerative diseases including Alzheimer’s...
It has been suggested that the activation of the complement system is involved in the pathogenesis of several neurodegenerative diseases including Alzheimer's...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 93
SubjectTerms Alzheimer Disease - cerebrospinal fluid
Biomarkers
Complement C3b - cerebrospinal fluid
Complement C4b - cerebrospinal fluid
Complement Factor B - cerebrospinal fluid
Complement Factor H - cerebrospinal fluid
Complement System Proteins - cerebrospinal fluid
Electrophoresis, Gel, Two-Dimensional
Humans
Mass Spectrometry
Multiple Sclerosis - cerebrospinal fluid
Neurodegenerative Diseases - cerebrospinal fluid
Neurodegenerative Diseases - diagnosis
Other
Parkinson Disease - cerebrospinal fluid
Title Complement Protein Isoforms in CSF as Possible Biomarkers for Neurodegenerative Disease
URI https://www.ncbi.nlm.nih.gov/pubmed/15920296
https://www.proquest.com/docview/19343540
https://www.proquest.com/docview/67873497
https://pubmed.ncbi.nlm.nih.gov/PMC3851089
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dT9swED-1IE17QXzso3wUP_A0KSNz7MR-QGgrqxioE9NWrW9RHLujUkmgaSX477lLUrp2IO0tUs5K5PP5fuc7_w7gKBVBZCPuvAR3Pk_QHV2Nivas8IfWKWGGjm4j976H531xMZCDBsybcdYTWDwb2lE_qf5k_PH-7uEUDf6kNHgpj-lg5JgShFHQhHV0SSFFYT2xSCdwXeFgTnSy6MPqi3org5dd0z94c7Vs8i8_1N2EjRpAss-Vxreg4bJteNWrU-Q78JssvKoJZ1dEwjDK2LciJ2xaMHzu_OyypGBXORnD2LEvo_yGSnQmBUMZVpJ1WPenZKOmrZCdVSmcN9Dvfv3VOffq7gleKj75U0-KYUAGGqU6NFKpIFFKYzCGMYsJnUmESUWC9p4Imxh0ZCbkVlP0paSwQ62Ct7CW5Zl7D0wGKSITJS3iBSEtN5o7P7WcRhBlVgs-zCcuTmtqcepwMY7LEENKanYp42qWW7hA5sK3FaPG82KHcw3EuOIpjZFkLp8VMUJOQadVL0ugA44CoaMWvKs0tviQ1NznOmxBtKTLJwFi215-k42uS9btALGpr_Tu__3-HrwuSV7Lw5p9WJtOZu4A4cvUtKF5-UO1ywX6CBXN68U
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Complement+protein+isoforms+in+CSF+as+possible+biomarkers+for+neurodegenerative+disease&rft.jtitle=Disease+markers&rft.au=Finehout%2C+Erin+J&rft.au=Franck%2C+Zsofia&rft.au=Lee%2C+Kelvin+H&rft.date=2005&rft.issn=0278-0240&rft.volume=21&rft.issue=2&rft.spage=93&rft_id=info:doi/10.1155%2F2005%2F806573&rft_id=info%3Apmid%2F15920296&rft.externalDocID=15920296
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0278-0240&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0278-0240&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0278-0240&client=summon